BioProspecting and Atlantic Cancer Research Institute establish formal collaboration to develop early diagnostic for ovarian cancer
BPNBI has been able to visualize human tumours growing in mice, where after the injection of fluorescent diagnostic material into the animals, the tumours light up. It shows that the therapeutic is so targeted to the biomarker that it can be used to identify the specific location of the tumour. (CNW Group/BioProspecting NB Inc. (BPNBI))
Dr. Rodney Ouellette, CEO, Atlantic Cancer Research Institute. (CNW Group/BioProspecting NB Inc. (BPNBI))
The unique fit between ACRI's work with cancer biomarkers and BPNBI's discoveries and development capabilities have allowed the two to move closer to an early diagnostic test for ovarian cancer. As there are no approved early diagnostics for this cancer, BPNBI believes it can fill this void.
The entry-level diagnostic is presently focused on a simple blood test to measure the amount of biomarker. Cancer tumours shed cells that circulate in the blood. Since the shed cells contain abundant biomarker, it can be detected. Such an increase in the amount of biomarker in a blood test would suggest to the clinician that further testing is in order.
"The novel biomarker that we are targeting is overproduced in ovarian, breast and prostate cancers, to name a few," says BPNBI's founder,
BPNBI is also pursuing a novel approach to cancer management that not only includes diagnosis but treatment as well. In fact, the diagnostic application builds on the exciting preclinical work that has shown the therapeutic is effective at decreasing growth of human ovarian tumours in mice while producing no noticeable negative side effects.
Upon returning recently from
Based on the early success of the diagnostic being developed, and because there is very little in the oncology field that can be done to detect early ovarian cancers, the commercialization of the diagnostic is a significant commercial opportunity for BPNBI.
BPNBI has already been able to visualize human tumours growing in mice (see graphic below), where after the injection of fluorescent diagnostic material into the animals, the tumours light up. It shows that the therapeutic is so targeted to the biomarker that it can be used to identify the very specific location of the tumour.
This ability is presently being adapted to operate in an MRI environment providing the clinician a non-invasive tool to track tumours before, during and after treatment in a highly quantitative manner.
BioProspecting NB, Inc. (BPNBI)
BioProspecting NB, Inc. is a private early-stage drug development company created in 2005 by
Atlantic Cancer Research Institute (ACRI)
The Atlantic Cancer Research Institute (ACRI) is a non-profit organization founded in 1998 and housed at the Dr. Georges-L. Dumont Regional Hospital in Moncton,
/NOTE TO PHOTO EDITORS: A photo accompanying this release is available at http://photos.newswire.ca. Images are free to accredited members of the media/
For further information: Professor Jack Stewart, Chief Scientific Officer, BioProspecting NB Inc., (506) 536-0014 ext. 104, firstname.lastname@example.org; Françoise Roy, Director of Communications and Development, Atlantic Cancer Research Institute, (506) 862-4221, email@example.com